Basic Toradol Information

• INN (International Nonproprietary Name): Ketorolac Tromethamine.
• Brand Names Available In United Kingdom: Toradol; Ketorolac.
• ATC Code: M01AB15.
• Forms & Dosages: Injection (10 mg/mL, 30 mg/mL), Oral Tablet (10 mg), Nasal Spray (Sprix — not widely marketed), Ophthalmic Solution (Acular 0.5%).
• Manufacturers In United Kingdom: Hoffmann‑La Roche (historical Toradol brand), plus generic suppliers such as Sandoz, Teva, Pfizer and Mylan.
• Registration Status In United Kingdom: Widely registered as a prescription‑only medicine.
• OTC / Rx Classification: Prescription‑only (Rx) — not available over the counter.

Key Findings From Recent Trials

Major 2022–2025 Studies

Are you wondering how ketorolac compares with opioids and other NSAIDs for acute pain?

Recent systematic reviews and randomised trials through 2022–2025 continue to place ketorolac among the most potent non‑opioid analgesics for short‑term moderate–severe pain, especially in postoperative settings.

Meta‑analyses comparing parenteral ketorolac with opioids report comparable pain reduction over the first 24–48 hours with less nausea and sedation but without long‑term superiority.

Hospital‑based trials favour IV/IM ketorolac for rapid onset versus oral NSAIDs, with nasal Sprix studies (mainly outside the United Kingdom) showing utility where parenteral access is limited.

Main Outcomes

• Rapid, high‑potency analgesia within 30–60 minutes for IM/IV administration.
• Comparable opioid‑sparing effect when used in multimodal analgesia protocols.
• Short‑course efficacy limited by the recommended maximum systemic duration of ≤5 days.

Safety Observations

Do the recent trials change the safety picture for ketorolac?

Recent data reaffirm an increased risk of gastrointestinal bleeding and acute kidney injury with higher doses and prolonged use.

Vulnerable populations such as the elderly and people with renal impairment show disproportionate harm, consistent with historical safety signals including the German withdrawal in 1993.

Use of ketorolac in hospital practice therefore emphasises brief courses, renal monitoring and strict contraindication checks.

Clinical Mechanism Of Action

Layman’s Explanation

How does ketorolac relieve severe pain so quickly?

Ketorolac is a non‑selective NSAID that reduces pain and inflammation by blocking COX‑1 and COX‑2 enzymes, which lowers prostaglandin production that sensitises pain receptors.

Parenteral formulations deliver fast analgesia and are useful for acute postoperative pain when oral intake may be restricted.

Scientific Breakdown

COX inhibition produces a fall in PGE2 and other prostaglandins responsible for nociception and inflammation.

Pharmacodynamics

Ketorolac has higher analgesic potency than many typical NSAIDs such as ibuprofen for short‑term severe pain due to stronger suppression of prostaglandin synthesis.

Pharmacokinetics

Available routes include IV/IM (rapid peak), oral 10 mg tablets, nasal spray (Sprix in North America), and ophthalmic Acular 0.5% for ocular inflammation.

Elimination is predominantly renal and impaired renal function increases plasma exposure and the risk of toxicity.

In the United Kingdom, ketorolac (Toradol) is prescription‑only and used mainly in hospital settings for short courses (≤5 days) because of renal and gastrointestinal risk.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

What is ketorolac licensed for in the UK?

Ketorolac is registered in injectable and tablet forms as a prescription‑only medicine for short‑term management of moderate–severe acute pain, particularly postoperative pain.

Ophthalmic ketorolac (Acular 0.5%) is approved for postoperative ocular inflammation.

Notable Off‑Label Trends

Which off‑label uses appear in practice?

Single IM/IV 30 mg doses are used off‑label in emergency departments for migraine abortive therapy with evidence of rapid relief in some studies.

Single‑dose parenteral regimens are also used in pre‑hospital care and ambulatory surgery to reduce immediate opioid need.

Nasal Sprix exists in the US and Canada but is not widely marketed in the UK.

Regulatory caveat: systemic ketorolac must not be used for more than five days because of GI and renal risks; prolonged off‑label use is contraindicated.

Dosage Strategy

General Dosing

What doses should clinicians use?

Standard adult dosing is oral 10 mg every 4–6 hours and parenteral 10–30 mg IV/IM every 6 hours, with a strict maximum systemic duration of five days.

UK practice favours the lowest effective parenteral dose — often a single 10–30 mg administration or q6h dosing — within an opioid‑sparing plan.

Condition‑Specific Dosing

How is dosing adjusted by condition?

For postoperative pain, the usual regimen is IM/IV 10–30 mg every six hours as part of multimodal analgesia with the shortest effective duration.

In emergency settings for acute migraine, a single IM/IV 30 mg dose is commonly used off‑label with close monitoring.

Ophthalmic use of Acular 0.5% follows ophthalmology guidance for conjunctival and postoperative inflammation.

Special Populations

Elderly patients should receive lower doses (for example 10 mg) and shorter courses with increased monitoring.

Renal impairment is an important contraindication or requires substantial dose reduction because elimination is renal.

Safety Protocols

Contraindications

Who must not receive ketorolac?

Absolute contraindications include active peptic ulcer disease or gastrointestinal bleeding, severe renal impairment, known NSAID hypersensitivity, bleeding diathesis, and use in late pregnancy and labour.

Product information also reiterates contraindication in renal failure and following prior NSAID‑related allergic reactions.

Adverse Effects

What side effects should be anticipated?

Common effects include nausea, dizziness, headache, indigestion and drowsiness.

Serious reactions include gastrointestinal bleeding, acute kidney injury, cardiovascular events, anaphylaxis and bronchospasm.

To reduce risk, systemic use is limited to five days or less.

UK clinical practice uses a pre‑administration checklist covering renal function, anticoagulant use, NSAID allergy history and age over 65, and documents informed consent for off‑label single‑dose uses.

Interaction Mapping

Food Interactions

Do meals affect ketorolac?

There are no major food–drug interactions, although oral absorption can be delayed with large meals.

Parenteral routes bypass gastrointestinal absorption issues.

Drug Combinations To Avoid

Which medicines increase risk when combined with ketorolac?

Anticoagulants and antiplatelets such as warfarin, DOACs and aspirin increase bleeding risk and are a major concern with ketorolac.

Combining ketorolac with other NSAIDs is contra‑indicated because of additive GI and renal toxicity.

Nephrotoxic agents such as ACE inhibitors, diuretics and aminoglycosides raise the risk of acute kidney injury when used together with ketorolac and require renal monitoring.

Concurrent corticosteroids increase the chance of gastrointestinal ulceration and bleeding.

Because ketorolac is a non‑selective COX inhibitor, interaction patterns mirror those of other NSAIDs and prescribers should always check renal function and the hospital formulary for local guidance.

Patient Experience Analysis

Survey Data

What do patients say about ketorolac?

Patient‑reported outcomes in acute postoperative cohorts show high early analgesic satisfaction with parenteral ketorolac compared with opioids due to less nausea and quicker mobilisation.

However, when patients are informed of renal and gastrointestinal risks they commonly prefer short courses only.

Forum Trends

What do online discussions reveal?

Forum posts and reviews frequently report rapid relief after IM/IV ketorolac, and less sedation than with opioids.

Other comments mention stomach pain or transient dizziness and some misconceptions such as expecting long‑term use, which underlines the importance of clear patient education.

NHS guidance frames ketorolac as a potent, short‑term option within multimodal pathways and recommends shared decision‑making for older patients or those on anticoagulants.

Distribution & Pricing Landscape

How easy is it for hospitals and clinics to source ketorolac in the UK?

Toradol was historically supplied by Hoffmann‑La Roche and generics are widely available from Sandoz, Teva, Pfizer and Mylan.

In the UK market, injectable and tablet generics and branded ketorolac supplies are carried on hospital formularies.

Generic ketorolac is typically low cost for the NHS, while parenteral ampoules and ophthalmic preparations such as Acular have higher unit costs.

Nasal Sprix is regionally limited to North America and is not a major supplier in the United Kingdom.

Injectable vials require careful handling and temperature‑stable transport, and occasional shortages can occur from manufacturing or distribution issues.

NHS trusts usually apply formulary restrictions such as short‑course limits and renal monitoring when ketorolac is listed.

Alternative Options

Comparison Summary

Which medicines are practical alternatives to ketorolac?

Ketorolac delivers high‑potency short‑term analgesia with renal and GI risks and is prescription‑only with parenteral and oral forms.

Ibuprofen is an OTC choice with lower potency for severe pain but a safer profile for brief use.

Naproxen offers longer half‑life and moderate potency; available OTC/Rx.

Diclofenac is effective and available in topical forms that reduce systemic exposure.

Opioids remain stronger for severe pain but carry risks of dependence, sedation and constipation.

Triptans such as sumatriptan are migraine‑specific abortive agents and are preferred for many patients with migraine.

Pros And Cons

Where does ketorolac sit in clinical decision‑making?

Pros include rapid onset, opioid‑sparing potential and availability as a parenteral option for inpatient care.

Cons include the strict ≤5‑day limit, renal and gastrointestinal risk and contraindications in many patients.

UK practice generally reserves ketorolac for monitored, short inpatient courses or selected emergency department use.

Regulatory Status

What is ketorolac’s regulatory standing?

Ketorolac tromethamine is classified under ATC M01AB15 and is prescription‑only across major markets including the UK and EU.

The ophthalmic formulation Acular 0.5% is approved for ocular inflammation.

Regulatory history includes withdrawal from the German market in 1993 because of gastrointestinal bleeding and renal failure concerns, a safety signal still reflected in current guidance limiting systemic treatment to five days.

In North America the original Toradol brand has been discontinued but generics and Sprix nasal spray have been available; in the UK generics from Sandoz, Teva, Pfizer and Mylan are common.

MHRA and NHS guidance in the United Kingdom aligns with short‑duration, monitored use and explicit contraindications.

Consolidated FAQ

Is Toradol available over the counter in the UK?

No — ketorolac is prescription‑only in the United Kingdom.

How long can I take ketorolac?

Systemic use is limited to five days or less to reduce gastrointestinal and renal risk.

Can I take ketorolac with warfarin or a DOAC?

That is not recommended because it increases bleeding risk; consult the prescriber.

Is ketorolac safer than opioids?

For short‑term postoperative pain it can reduce opioid requirements and typically causes less sedation and nausea, but it has GI and renal risks that opioids do not carry.

Can pregnant or breastfeeding people use ketorolac?

It is contraindicated in late pregnancy and should be used with caution or avoided while breastfeeding.

Are the eye drops (Acular) the same as systemic ketorolac?

Ophthalmic ketorolac 0.5% is a separate formulation used for ocular inflammation and has different safety considerations than systemic dosing.

Visual Guide

Would a simple visual help ward staff and patients?

Recommended graphics include a dosing ladder showing IV/IM 10–30 mg to oral 10 mg with a clear five‑day maximum timeline.

A pre‑administration checklist flowchart should prompt checks for renal function, bleeding risk, NSAID allergy and concomitant medicines.

A decision tree for postoperative analgesia can show when a parenteral bolus of ketorolac is appropriate within multimodal pathways and when to switch to oral non‑opioids.

Use icons for contraindication alerts (renal, GI bleed, pregnancy) and monitoring prompts such as creatinine checks.

Storage & Transport

How should ketorolac be stored and moved within the hospital?

Store tablets and injectables at room temperature between 15–25°C and protect from moisture and light.

Do not freeze injectables and handle glass ampoules and vials carefully to avoid contamination.

Ophthalmic bottles of Acular have manufacturer‑specific handling instructions which should be followed.

When transporting stock around the hospital, keep products in their original packaging with prescription and administration records and document storage conditions in ward stock records.

Dispose of unused parenteral ampoules safely according to local policy.

Guidelines For Proper Use

How should ketorolac be used safely in UK practice?

Reserve systemic ketorolac for short‑term inpatient or emergency use where potential benefits outweigh risks.

Protocols should include a baseline renal check before the first dose, review of anticoagulant therapy, a limit of five days total duration and use of the lowest effective dose.

Document informed consent for off‑label indications such as migraine when a single IM/IV 30 mg dose is used.

Monitor renal function in at‑risk patients, observe for signs of GI bleeding and watch for respiratory reactions in NSAID‑sensitive asthmatics.

Include ketorolac on hospital formularies with explicit contraindications and decision‑support alerts in e‑prescribing systems.

Patient counselling should stress the short‑course intent and warning signs such as stomach pain or reduced urine output.

Delivery Across United Kingdom

Concluding Practical Notes

Is it straightforward for patients to obtain ketorolac in the UK?

Ketorolac remains prescription‑only in the United Kingdom, and prescribers must follow contraindication checks and the ≤5‑day rule.

In our online pharmacy, toradol is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

For clinicians, include ketorolac in multimodal analgesia protocols when rapid parenteral analgesia is needed and ensure renal monitoring and avoidance in high‑risk patients.

For patients, ask about stomach ulcer history, current anticoagulant therapy and kidney disease before accepting ketorolac, and report any abdominal pain or reduced urine output promptly.

When used appropriately, ketorolac offers powerful, short‑term pain relief while helping to reduce early opioid exposure in the postoperative and emergency setting.